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Abstract
Alveolar rhabdomyosarcoma (ARMS) has a much poorer prognosis than themore common embryonal subtype. Most
ARMS tumors characteristically possess a specific genomic translocation between the genes of PAX3/7 and FOXO1
(FKHR), which forms fusion proteins possessing the DNA binding domains of PAX3/7 and the more transcriptionally
potent transactivation domain of FOXO1. We have shown that the proapoptotic BH3-only family member Noxa is
upregulated by the PAX3-FOXO1 fusion transcription factor in a p53-independent manner. The increased expression
of Noxa renders PAX3-FOXO1–expressing cells more susceptible to apoptosis induced by a γ-secretase inhibitor
(GSI1, Z-LLNle-CHO), the proteasome inhibitor bortezomib, and BH3 mimetic ABT-737. Apoptosis in response to
bortezomib can be overcome by shRNA knockdown of Noxa. In vivo treatment with bortezomib reduced the
growth of tumors derived from a PAX3-FOXO1–expressing primary myoblast tumor model and RH41 xenografts.
We therefore demonstrate that PAX3-FOXO1 up-regulation of Noxa represents an unanticipated aspect of ARMS
tumor biology that creates a therapeutic window to allow induction of apoptosis in ARMS cells.
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Introduction
Rhabdomyosarcoma (RMS) is the most prevalent soft tissue sarcoma
in children. RMS is thought to be derived from cells of mesenchymal
lineage and tumors express muscle-specific markers such as MYO-D,
desmin, myoglobin, and proteins of the contractile apparatus. RMS con-
sists of two main histologic cell types, embryonal and alveolar RMS
(ERMS and ARMS, respectively). ERMS is thought to resemble em-
bryonic developing muscle, while ARMS contains alveolar structures
resembling lung tissue in appearance [1]. Of these two subtypes, ARMS
is the most aggressive and has the poorest prognosis [1,2].
ARMS tumors are associated with chromosomal translocations be-
tween the PAX3 or PAX7 and FOXO1 genes in approximately 55%
and 22% of cases, respectively [3]. In addition, other similar rare trans-
locations of the PAX3 gene to that of other transcription factors (AFX,
NCOA1, and NCOA2) have been identified in ARMS [4–6]. Fusion
of the PAX3 DNA binding domain to the more potent transactivation
domain of FOXO1 results in a fused transcription factor with stronger
transcriptional activity than wild-type PAX3 [7]. Within the ARMS
subtype, tumors expressing the PAX3-FOXO1 fusion protein are asso-
ciated with the poorest prognosis, particularly if the patient presents
with metastatic disease [3]. Moreover, a single copy of PAX3-FOXO1
is usually found in ARMS, while PAX7-FOXO1 often shows genomic
amplification of the fusion allele [8], supporting the notion that PAX3-
FOXO1 is a more potent oncogene than PAX7-FOXO1. Therefore,
we have identified genes regulated by PAX3-FOXO1 to determine if
these could represent viable novel therapeutic targets for the treatment
of ARMS [9,10].
In the treatment of more aggressive cancer types, which are resistant
to traditional chemotherapeutics, new strategies are being developed
to target these diseases. Several new drugs are showing promise in a
variety of different cancer types at specifically inducing apoptosis in
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cancer cells. Bortezomib (PS-341, Velcade) is a potent 26 S proteasome
inhibitor, which causes the accumulation of misfolded or unfolded pro-
teins in the endoplasmic reticulum, inducing endoplasmic reticulum
stress. The accumulation of these unfolded proteins results in the un-
folded protein response [11]. Bortezomib treatment also stabilizes pro-
apoptotic factors that are normally degraded through the proteasome
[12]. The cumulative effect of bortezomib treatment is induction of
apoptosis. Bortezomib is currently approved by the Food and Drug
Administration (FDA) for treatment of multiple myeloma and refrac-
tory mantle cell lymphoma, and phase II trials are underway for multi-
ple other cancer types including solid tumors [13]. Another potential
cancer therapy consists of γ-secretase inhibitors (GSIs), which were
originally designed for the treatment of Alzheimer’s disease [14] but
have since been investigated as potential cancer therapies to target
tumor cells with high Notch expression [15]. Though they may show
promise in some tumor types that are not Notch dependent [16], GSIs
have been found to cause severe gastrointestinal toxicity due to goblet
cell metaplasia induced by Notch inhibition [17]. Recent findings,
however, have shown that co-treatment with glucocorticoids can pro-
tect the gut of mice from GSI toxicity [18], renewing interest in GSIs as
anticancer therapeutics. Both GSI1 (Z-LLNle-CHO) and bortezomib
have been shown to induce melanoma cell apoptosis while sparing
normal melanocytes. Both compounds specifically induce the mRNA
and protein expression of the proapoptotic BH3-only factor, Noxa/
Pmaip1, which in turn induces mitochondrial-based apoptosis in a
p53-independent manner [19,20]. The effect of GSI1 on RMS has
not, to the author’s knowledge, been investigated in ARMS. However,
bortezomib has been shown to induce apoptosis in some ERMS- and
ARMS-derived cell lines and reduce growth of some tumors in a xeno-
graft model [21,22].
In this study, we have found that the ARMS-associated PAX3-
FOXO1 fusion oncogene specifically upregulates proapoptotic BH3-
only factor Noxa, in a p53-independent manner. Up-regulation of
Noxa by PAX3-FOXO1 sensitizes the cells to treatment with GSI1
and bortezomib that also induces Noxa-dependent, p53-independent,
apoptosis. In addition, apoptosis is induced in PAX3-FOXO1 cells
treated with ABT-737 that targets antiapoptotic Bcl-2, Bcl-xL, and
Bcl-w, while Noxa inhibits antiapoptotic MCL-1, representing a dual
approach to induce mitochondrial apoptosis specifically in PAX3-
FOXO1–expressing cells. Treatment with bortezomib was sufficient to
reduce the growth of tumorigenic primary mouse myoblasts expressing
PAX3-FOXO1 and human RH41 ARMS xenografts in vivo. Thus, we
have illustrated the validity of such Noxa-inducing factors as potential
therapies, specifically targeted to fusion-positive ARMS tumors.
Materials and Methods
Cell Culture
Primary myoblasts were isolated from 1- to 5-day-old C57Bl6/J,
p53−/− [23] or wild-type control, or Arf −/− [24] mice and cultured ac-
cording to Marshall et al. [9]. RMS lines were cultured in Dulbecco’s
modified Eagle’s medium and 10% Cosmic calf serum following stan-
dard procedures. These cell lines were obtained from Dr Houghton
(Nationwide Children’s Hospital) in 2005 and were authenticated by
Western blot to express PAX3-FOXO1 and skeletal muscle markers
(data not shown). Human skeletal muscle myoblasts (HSMMs; Lonza,
Allendale, NJ) were cultured according to the supplier’s instructions.
HSMMs were obtained from Lonza and have undergone less than
10 passages and were authenticated by Western blot to express skeletal
muscle markers (data not shown).
Cells were transduced with retroviral constructs packaged using
phoenix Eco cells [25] consisting of MSCV backbone with PAX3
or PAX3-FOXO1 followed by an internal ribosome entry site–green
fluorescent protein (IRES-GFP) or an SV40 promoter–puromycin
gene to allow selection of transduced cells by fluorescence-activated cell
sorting (FACS) or puromycin treatment, respectively. shNoxa targeted
the sequence 5′-CAACACTGAATGTTCTAGTGAA-3′ in the context
of pre–miR-30 sequences to ensure correct processing.
Real-Time Polymerase Chain Reaction
RNA was isolated by TRIzol (Invitrogen), and reverse transcription–
polymerase chain reaction (PCR) was performed using the SuperScript
III First-Strand Synthesis System for RT-PCR (Invitrogen, Green Island,
NY) according to the manufacturer’s protocol. Real-time PCR was then
performed using TaqMan Universal PCR Master Mix (Applied Bio-
systems, Green Island, NY), 0.3 μM primers, and 0.2 μM probes as
follows: mNoxa Fwd, 5′-CTGTGGTTCTGGCGCAGAT-3′; mNoxa
Rev, 5′-TGGCTGTATCTCTCCACAAGTTCT-3′; mNoxa Probe,
5′-CTGGGAAGTCGCAAAA-3′ (5′-FAM/3′-BHQ1); hNoxa Fwd,
5′-GAGCTGGAAGTCGAGTGTGCTA-3′; hNoxa Rev, 5′-TGCC-
GGAAGTTCAGTTTGTCT-3′; hNoxa Probe, 5′-TCAACTCAGGA-
GATTTG-3′ (5′-FAM/3′-BHQ1); hMCL-1 Fwd, 5′-GTTGACC-
AGAAAGGACACTCCAT-3′; hMCL-1 Rev, 5′-CAATCGTTTCCA-
TATCAGTCAGAAA-3′; hMCL-1 Probe, 5′-TGTGAAACCGGCC-
TAAT-3′ (5′-FAM/3′-BHQ1); hA1 Fwd, 5′-CCTGGATCAGGTC-
CAAGCAA-3′; hA1 Rev, 5′-TTGGACTGAGAACGCAACATTT-
3′; hA1 Probe, 5′-TTGGACTGAGAACGCAACATTT-3′ (5′-FAM/
3′-BHQ1). Real-time PCR results were normalized to endogenous
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression using
the real-time primer/probe set Mouse GAPDH Endogenous Control
(VIC/MGB Probe, Primer Limited; Applied Biosystems 435 2339) as
per the manufacturer’s instructions. All real-time PCRs were performed
using the ABI Prism 7900HT and SDS2.1 software (Applied Biosystems).
Western Blot Analysis
Whole-cell extracts were prepared in cell lysis buffer (Cell Signaling
Technology, Beverly, MA), and protein concentration was determined
using Bio-Rad protein assay reagent as per the manufacturer’s instruc-
tions. Protein (10 μg) was run out on 4% to 12% or 12% NuPAGE
Bis Tris Gels (Invitrogen) and transferred to nitrocellulose membrane
using the iBlot System (Invitrogen). Gels were blocked in 5% nonfat
dry milk in tris-buffered saline with Tween 20 (TBST), and primary
antibody was applied in 5% milk or BSA in TBST overnight at
4°C and washed five times for 5 minutes in TBST; secondary HRP-
conjugated antibody was applied in 5% milk in TBST for 1 hour at
room temperature and washed, andHRP visualization was performed us-
ing Western Lightening (PerkinElmer, Waltham, MA) or Pico/Femto
(Thermo Scientific, Pittsburgh, PA) chemiluminescent reagent. Anti-
bodies were used at the following concentrations: 1:1000 rabbit anti-
PAX3 [26], 1:1000 rabbit anti-Noxa (ab36833; Abcam, Cambridge,
MA), 1:1000 rabbit anti–Bmi-1, anti-Bim, anti-Bax, anti-Bak, anti-
Bad, anti-Puma, anti–Bcl-2, anti–Bcl-xL, anti–Bcl-w (Cell Signaling
Technology), 1:1000 anti-Bid (BD Pharmingen, Franklin Lakes, NJ),
1:4000, rabbit anti–MCL-1 (Sigma, St Louis, MO), 1:1000 rabbit
anti–Pan-actin (Cell Signaling Technology), and goat anti-rabbit HRP
(Jackson Laboratories, Bar Harbor, ME).
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Caspase-3/7 Activity Assay
Primary myoblasts expressing PAX3-FOXO1 or empty vector were
plated at 1000 to 2000 cells per well of a 96-well collagen coated plate
(Becton Dickinson, Franklin Lakes, NJ). Twenty-four hours later,
primary myoblasts were treated for 8 hours with indicated concentra-
tions of GSI1 (Z-LLNle-CHO; Calbiochem, Darmstadt, Germany),
bortezomib (LC Laboratories, Woburn, MA), or ABT-737 (Abbott
Laboratories, Abbott Park, IL). ARMS cell lines were plated similarly
and, 24 hours later, treated with drugs for 24 hours. Caspase-3/7 activity
was determined using the Apo-ONE Homogeneous Caspase-3/7 Assay
(Promega, Madison, WI) according to the manufacturer’s instructions.
Cytochrome c Immunostaining
Cytochrome c staining was performed according to the protocol
of Tait et al. [27]. Briefly, cells were plated on glass coverslips, and
24 hours later, cells were treated with 50 nM bortezomib for 24 hours.
Then, cells were fixed in 4% paraformaldehyde for 20 minutes at room
temperature. Cells were then permeabilized with phosphate-buffered
saline (PBS) and 0.1% Triton for 10 minutes. Cells were blocked for
30 minutes in PBS, 0.1% Triton X-100, and 0.5% BSA, followed by
1:200 anti–cytochrome c (BD Pharmingen; 556432) in blocking buf-
fer overnight at 4°C. Cells were then washed five times in TBS and
0.05% Tween 20 and incubated with Alexa Fluor 488 goat anti-
mouse antibody (Invitrogen) for 1 hour at room temperature. Samples
were washed again and mounted in Vectashield mounting medium
with 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories,
Burlingame, CA), and fluorescent micrographs were taken.
In Vivo Bortezomib and ABT-737 Treatment
NOD-scid IL2Rγnull [28] mice were injected with 1 × 106 Arf −/− E7
PAX3-FOXO1 (30 animals total), PAX3 (5 animals), and empty vector
(Empty) expressing (5 animals) primary myoblasts. Tumors were left to
grow for 17 days at which time all mice had palpable tumors of at least
4-mm diameter. Mice were then treated twice a week for 2 to 4 weeks
by tail vein injection with 0.8 mg/kg bortezomib (NCI/Millennium
Pharmaceuticals, Cambridge, MA) in PBS, 75 mg/kg per day ABT-737
intraperitoneal (i.p.) in vehicle [30% propylene glycol, 5% Tween 80,
and 65% dextrose (5%) in water], or 0.4 mg/kg bortezomib twice
weekly intravenous (i.v.) and 75 mg/kg per day ABT-737 i.p. Per
treatment, 15 animals were used for bortezomib only, 7 animals for
ABT-737 only, and 6 animals for bortezomib and ABT-737 treatment.
Tumors were monitored and measured daily with calipers, and mice
were humanely killed once the tumor size reached 20% of their body
weight and the tumor became ulcerated or interfered with animal
mobility or function, adhering to the humane end points according
to St Jude Institutional Animal Care and Use Committee (IACUC)
protocol. Mice were monitored during treatment for signs of toxicity
including weight loss, dehydration, and lethargy.
RH30 and RH41 xenografts were performed according to the Pedi-
atric Preclinical Testing Program protocols as described by Houghton
et al. [29] except that tumors were implanted subcutaneously in NOD-
scid IL2Rγnullmice [28]. Six animals were used per treatment group and
tumors were allowed to grow as above, before bortezomib treatment,
and monitored as above.
Statistics
Statistical differences were determined by using a two-tailed t test,
assuming equal variances. Survival curve differences were determined
using the log-rank (Mantel-Cox) test in GraphPad Prism 5.02 software.
P values are indicated by */‡P < .05, **P < .01, and ***P < .001.
Results
PAX3-FOXO1 Induces the Expression of Proapoptotic
BH3-Only Protein Noxa in a p53-Independent Manner
Upon conducting microarray analysis of primary mouse myoblasts,
expressing either empty vector, PAX3, or PAX3-FOXO1, Noxa was
found to be specifically upregulated in PAX3-FOXO1–expressing cells
(data not shown). This result was confirmed by real-time PCR com-
paring the expression of Noxa in primary myoblasts transduced with
empty, PAX3, or PAX3-FOXO1 murine stem cell virus–internal ribo-
some entry site–green fluorescent protein (MSCV-IRES-GFP) retrovirus.
This showed an increase in Noxa mRNA expression of 7.11 ± 1.63-fold
(mean ± range, P < .001) in PAX3-FOXO1 over empty vector control
cells (Figure 1A). The increase in Noxa expression in PAX3-FOXO1–
expressing primary myoblasts can also be seen at the protein level
(Figure 1B). Moreover, the mRNA expression of Noxa in PAX3-
FOXO1 fusion–positive ARMS cell lines (RH30, RH4, RH41, RH3,
RH28) was found to be upregulated 4-fold to 10-fold in all lines com-
pared to Lonza HSMMs (Figure 1E ). Given that Noxa is a known
transcriptional target of p53 [30], we investigated whether the in-
duction of Noxa by PAX3-FOXO1 was dependent on the p53 path-
way by repeating the same experiment in Arf −/− and p53−/− primary
myoblasts. The basal levels of Noxa expression are lower in Arf −/− and
p53−/− primary myoblasts, likely because p53 transcriptionally activates
Noxa expression [30]. PAX3-FOXO1 expression in these cell types
continued to upregulate Noxa expression over empty vector control
levels in the same cell type (Figure 1, C and D), indicating that PAX3-
FOXO1 induction of Noxa expression is independent of p53 activity.
We hypothesized that due to PAX3-FOXO1 up-regulation of
Noxa, inhibition of Noxa activity might be required for ARMS tumori-
genesis. The open reading frame of Noxa was sequenced and coded for
wild-type Noxa protein in all ARMS lines and HSMMs (data not
shown). Investigation of the mRNA expression levels of the Noxa
antiapoptotic targets MCL-1 and A1 showed no correlation with
Noxa expression (Figure 1, F and H ). Because the levels of MCL-1
are also posttranslationally regulated by proteasome-dependent and
proteasome-independent mechanisms [31,32], we examined the pro-
tein expression level of MCL-1 and A1. MCL-1 protein expression
did differ frommRNA expression considerably; MCL-1 protein expres-
sion was upregulated in four of five ARMS lines: RH4, RH41, RH3,
and RH28 over HSMMs (Figure 1G). This indicates that MCL-1 pro-
tein expression is increased through a posttranslational mechanism in
these ARMS cell lines. A1 protein expression was below detection by
Western blot (data not shown).
PAX3-FOXO1 Induction of Noxa Increases Myoblast
Susceptibility to GSI1, Bortezomib, and ABT-737
Both GSI1 and bortezomib have been shown to induce p53-
independent activation of Noxa resulting in apoptosis [19,20]. We
tested if PAX3-FOXO1 induction of Noxa in primary mouse myoblasts
would increase the susceptibility of these cells to undergo apoptosis
upon treatment with these two drugs. In both wild-type and Arf −/−
primary myoblasts, apoptosis was increased in a dose-dependent
manner in cells expressing PAX3-FOXO1 compared to empty vec-
tor controls (Figure 2, A and B). By Western blot, both GSI1 and
bortezomib treatment increased Noxa protein expression in primary
740 PAX3-FOXO1 Induces Up-Regulation of Noxa Marshall et al. Neoplasia Vol. 15, No. 7, 2013
Figure 1. PAX3-FOXO1 induces Noxa expression in a p53-independent manner. (A) Relative mRNA expression of mouse Noxa deter-
mined by an average of two independently transduced primary myoblast samples by real-time PCR and normalized to GAPDH expres-
sion in primary myoblasts expressing PAX3, PAX3-FOXO1 (PF), or empty vector (Empty) and expressed as fold over empty vector
control. (B) Western blots using anti-PAX3 antibody to detect PAX3 and PAX3-FOXO1, anti-Noxa antibody to detect Noxa, and anti–
Pan-actin antibody as a loading control. Representative relative mRNA expression determined by real-time PCR comparing the expres-
sion of mouse Noxa in (C) Arf−/− and (D) p53−/− primary myoblasts and wild-type controls expressing PAX3, PAX3-FOXO1 (PF), or empty
vector (Empty), normalized to GAPDH and expressed as fold over wild-type (WT) empty vector control; * indicates significance from
appropriate empty vector control, and ‡ indicates significance fromWT empty vector control. (E) Representative relative mRNA expression
determined by real-time RT-PCR for human Noxa in ARMS cell lines RH30, RH4, RH41, RH3, and RH28 compared to HSMMs (Lonza)
normalized to GAPDH and expressed as fold over HSMM control. (F) Representative relative expression of human MCL-1 mRNA de-
termined by real-time PCR normalized to GAPDH expression, expressed as fold over HSMM control. (G) MCL-1 protein expression deter-
mined by Western blot; Pan-actin is provided as a loading control. (H) Representative relative expression of human A1 mRNA determined
by real-time PCR normalized to GAPDH expression, expressed as fold over HSMM control.
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myoblasts and, to a greater extent, in myoblasts expressing PAX3-
FOXO1 (Figure 2C ). Moreover, PAX3-FOXO1 expression reduced
the protein expression of MCL-1 (Figure 2C) but not mRNA expres-
sion (Figure W1A). Increased Noxa expression can result in MCL-1
degradation [33]. This is likely the mechanism for PAX3-FOXO1
down-regulation of MCL-1 protein seen in primary myoblasts.
Due to the priming for apoptosis by Noxa induction, downstream
of PAX3-FOXO1, we hypothesized that PAX3-FOXO1–expressing
myoblasts may be more susceptible to compounds that induce apop-
tosis through inhibition of other antiapoptotic factors. The compound
ABT-737 is known to selectively inhibit prosurvival factors Bcl-2,
Bcl-xL, and Bcl-w but has no significant inhibitory effect on MCL-1
activity [34]. PAX3-FOXO1–expressing wild-type myoblasts were
preferentially induced to undergo apoptosis in response to treatment
with ABT-737 in a dose-dependent manner (Figure 2D). On the pro-
tein level, ABT-737 treatment of primary myoblasts resulted in a small
Figure 2. PAX3-FOXO1–expressing cells are more susceptible to apoptosis upon treatment with Z-LLNle-CHO (GSI1) or bortezomib.
(A) Representative relative caspase activity of wild-type (WT) primary myoblasts expressing PAX3-FOXO1 (PF) or empty vector (Empty) con-
trol treated for 8 hours with increasing concentrations of GSI1 or bortezomib. Values are expressed as fold over untreated controls.
(B) Representative relative caspase activity of Arf−/− primary myoblasts expressing PAX3-FOXO1 (PF) or empty vector (Puro) control treated
for 8 hours with increasing concentrations of GSI1 or bortezomib. Values are expressed as fold over untreated controls. (C) Western blot of
theWT primary myoblasts treated for 8 hours with vehicle alone or 2.5μMGSI1 or 50 nM bortezomib (Bort) for Noxa andMCL-1 expression.
Pan-actin is used as a loading control. (D) Representative relative caspase activity of WT primary myoblasts expressing PAX3-FOXO1 (PF)
or empty vector (Empty) control treated for 8 hours with increasing concentrations of ABT-737. (E) Relative Noxa mRNA expression in
Arf−/− primary myoblasts expressing either a nontargeting (shNT) or Noxa-targeting (shNoxa) shRNA in control (Empty) and PAX3-FOXO1
myoblast lines. (F) Western blot for PAX3-FOXO1 andMCL-1 expression in Arf−/− control (Empty) and PAX3-FOXO1 primary myoblasts with
nontargeting (shNT) or Noxa shRNA (shNoxa) knockdown. A Pan-actin loading control is provided. (G) Representative relative caspase
activity in Arf−/− primary myoblasts expressing either a nontargeting (shNT) or Noxa-targeting (shNoxa) shRNA in control (Empty) and
PAX3-FOXO1 myoblasts in the presence of 50 nM bortezomib. Values are expressed as fold over appropriate controls.
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increase in MCL-1 protein expression. However, MCL-1 protein is
decreased in the presence of PAX3-FOXO1, and ABT-737 treatment
results in a significant down-regulation of PAX3-FOXO1 and Noxa,
indicating this increase in MCL-1 expression is partly downstream of
PAX3-FOXO1 induction of Noxa (Figure W1, D–F ).
To confirm that this increased propensity for bortezomib-induced
apoptosis in PAX3-FOXO1–expressing myoblasts was Noxa depen-
dent, we performed shRNA knockdown of Noxa expression in both
empty vector and PAX3-FOXO1–expressing myoblasts and were able
to reduce Noxa mRNA expression levels by about 65% (Figure 2E)
in both empty vector and PAX3-FOXO1–expressing cells. shRNA
knockdown of Noxa did not affect the expression level of PAX3-
FOXO1 in these cells (Figure 2F). However, Noxa shRNA expression
did result in a partial rescue of MCL-1 expression levels (Figure 2F).
Therefore, Noxa up-regulation contributes to the loss of MCL-1 pro-
tein expression seen with PAX3-FOXO1 expression (Figures 2, C and
F , and W1D). The approximately 65% knockdown of Noxa was
sufficient to completely abrogate the enhanced apoptosis seen in
Figure 3. Apoptotic response of ARMS cell lines to ABT-737 and bortezomib treatment. Representative relative caspase activity of ARMS
cell lines in response to treatment for 24 hours with increasing concentration of (A) ABT-737 and (B) bortezomib. (C) Western blots show-
ing the protein expression of apoptotic pathway members in response to 50 nM bortezomib treatment in ARMS cell lines. Pan-actin is
provided as a loading control. (D) Representative cytochrome c staining in ARMS cell lines treated with bortezomib. Arrows indicate cells
where cytochrome c release has occurred and cytoplasmic cytochrome c can be detected.
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PAX3-FOXO1–expressing cells in the presence of 50 nM bortezomib
(Figures 2G and W1B), indicating that this increased sensitivity of
PAX3-FOXO1 to bortezomib-induced apoptosis is entirely due to
Noxa up-regulation by PAX3-FOXO1. Similar abrogation of ABT-
737–induced apoptosis was seen with Noxa shRNA expression
(Figure W1C ).
PAX3-FOXO1 Induction of Noxa Induces Apoptosis in
Some, but Not All, ARMS Cell Lines
We also tested the sensitivity of the RH30, RH4, RH41, RH3, and
RH28 ARMS cell lines to bortezomib and ABT-737, all of which
express PAX3-FOXO1. ABT-737 induced apoptosis after 24 hours
in all five ARMS cell lines (Figure 3A). Similar to primary myoblasts,
ABT-737 upregulated MCL-1 concurrently with down-regulation of
PAX3-FOXO1 (Figure W1E ) though Noxa remained undetectable
by Western blot (data not shown). RH30, RH41, and RH28 showed
a significant apoptotic response after a 24-hour treatment with 50 nM
bortezomib (Figure 3B), a concentration sufficient to cause apoptosis
in primary myoblasts (Figure 2, A and B). Western blot analysis of
these cells indicated that in response to treatment with bortezomib,
all five cell lines upregulated Noxa protein expression (Figure 3C ).
MCL-1 protein expression was also upregulated by bortezomib in all
cell lines, likely due to inhibition of MCL-1 proteasome degradation
[16,22]. This increase in MCL-1 did not correlate with the survival
seen in RH4 and RH3 and therefore does not account for the re-
sistance of these cell lines to bortezomib treatment. Downstream of
MCL-1, there is no mutation in direct pathway members (data not
shown) nor is there a specific up-regulation of any prosurvival factor
(BCL-2, BCL-xL, BCL-w) or down-regulation of any specific pro-
apoptotic factor (BIM, BAX, BAK1, BAD, PUMA, tBID), which
could account for the survival of RH4 or RH3 and the absence of
cytochrome c release in these two surviving cell lines (Figure 3D).
Moreover, upon bortezomib treatment, Noxa interacts with MCL-1
in both the susceptible RH30 and the resistant RH4 ARMS cell lines
(Figure W1G). These cells are capable of undergoing apoptosis down-
stream of ABT-737 treatment, indicating that RH4 and RH3 have
specifically lost the ability to undergo apoptosis in response to in-
creased levels of Noxa, though the mechanism leading to this resistance
remains unclear.
Bortezomib Treatment In Vivo Reduces Tumor Growth
Arf −/− primary myoblasts (1 × 106) ectopically expressing E7 and
PAX3-FOXO1 were injected subcutaneously into the hind flank of
NOD-scid IL2Rγnull mice. Seventeen days later, all animals harbored
palpable tumors of at least 4 mm in diameter and were treated twice
weekly with 0.8 mg/kg per day bortezomib i.p. Animals lost a statis-
tically significant amount of body mass following bortezomib treat-
ment but regained weight 2 days after treatment (Figure 4A). Tumor
dimensions were measured daily and animals treated with bortezomib
showed a statistically significant reduction in tumor growth compared
to PBS-treated controls (Figure 4, B and C); this was concurrent with
a significant reduction in proportional tumor viability (Figure W2).
Animals were sacrificed in accordance with animal welfare guidelines
when the tumor reached 20% of the body mass (11/15 PBS, 12/15
bortezomib), the tumor became ulcerated (4/15 PBS), or because
of tumor-induced paralysis not allowing the animal to reach food
or water (1/15 Bort). In addition, 2/15 (13%) animals died due to
bortezomib toxicity consistent with previously reported toxicity rates
[22]. Comparing survival based on the day morbidity was reached,
bortezomib-treated mice showed a small but significant increase in
survival over vehicle alone (Figure 4D).
Treatment of this ARMS tumor model with ABT-737 at 75 mg/kg
per day i.p. alone did not produce a large difference in tumor growth
rate (Figure 4E) nor did it result in an increase in animal survival to
morbidity (data not shown). We also wished to determine if a combi-
nation treatment of ABT-737 at 75 mg/kg per day i.p. and bortezomib
at 0.4 mg/kg (half of concentration of bortezomib as a single agent)
twice weekly i.v. could act synergistically in this model (Figure 4F ).
Initially, we found that the combination treatment appeared to work
more effectively than 0.8 mg/kg twice weekly bortezomib i.v. treat-
ment. However, the mice showed signs of accumulated toxicity by
day 9, and treatment was ceased.
In addition, we tested the efficacy of bortezomib against RH30 and
RH41 xenografts. RH28 xenografts have already been shown to re-
spond when bortezomib was delivered i.p., but the RH30 and RH41
xenografts were unresponsive in this study [22]. However, in the clinic,
bortezomib is administered i.v. and the NCI drug repository (personal
communication) stated that bortezomib has poor bioavailability i.p.
So we repeated the treatment of the same xenograft tumors using i.v.
administration of bortezomib. RH41 showed a significant reduction
in growth with bortezomib treatment i.v. (Figure 5, A and B), but
RH30 did not respond (Figure 5, C and D), despite the induction
of apoptosis in vitro (Figure 3A). Consistent with this result, the viable
portion of tumor was reduced in RH41 treated with bortezomib but
not RH30 (Figures W3 and W4).
Discussion
We have shown that the ARMS-specific fusion gene PAX3-FOXO1
induces the expression of the proapoptotic BH3-only protein Noxa.
Previously, it has been reported that expression of PAX3-FOXO1 in-
duces apoptosis, and over time in culture, there is selection against
high expressers of PAX3-FOXO1 [35]. We reasoned that if Noxa
up-regulation limits the level of PAX3-FOXO1 expression, further
increasing Noxa expression with drug treatment would induce apop-
tosis in PAX3-FOXO1–expressing cells at concentrations that do not
affect controls. Indeed, this was the case. Both GSI1 and bortezomib
are known to induce apoptosis in different cancer types through the
p53-independent up-regulation of Noxa [16,19,20]. Like bortezomib,
GSI1 can, in addition to inhibiting γ-secretase activity, inhibit pro-
teasomal degradation indicating that the mechanism by which they
induce apoptosis in myoblasts may be similar [16]. Primary mouse
myoblasts expressing PAX3-FOXO1 are more susceptible to apoptosis
induced by these drugs than empty vector counterparts. This is entirely
due to PAX3-FOXO1 induction of Noxa expression as shRNA knock-
down of Noxa completely abrogates this increase in apoptosis seen in
PAX3-FOXO1–expressing primary myoblasts.
The BH3 mimetic compound ABT-737 specifically inhibits pro-
survival factors Bcl-2, Bcl-xL, and Bcl-w in the nM range while show-
ing low affinity for less homologous family members: MCL-1 and A1
[34]. High expression levels of MCL-1 have been shown to confer
resistance to ABT-737, and sensitivity to ABT-737 is reestablished if
MCL-1 levels are reduced [36]. The induction of Noxa expression
allows an increase in association of Noxa with MCL-1, which inhibits
MCL-1’s antiapoptotic activity and can also promote proteasomal
degradation of MCL-1 [37]. Consistent with this, we have found that
PAX3-FOXO1–expressing myoblasts, which have increased Noxa and
decreased MCL-1 protein expression, are more sensitive to ABT-737
treatment. ABT-737 treatment of both primary myoblasts and ARMS
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Figure 4. In vivo administration of bortezomib inhibits the growth of transformed primary myoblasts expressing PAX3-FOXO1. Fifteen
animals per PAX3-FOXO1 treatment group and five animals each for empty vector (Empty) and PAX3 were used for i.v. bortezomib treat-
ment. (A) Mouse body weight following treatment with 0.8 mg/kg twice weekly bortezomib i.v. (B) Fold change in tumor volume and
(C) change in tumor volume in cm3 as calculated from tumor width and length measurements. (D) Survival of animals to morbidity from
subcutaneous injection of cells. (E) Change in tumor volume in cm3 in seven mice per treatment group when treated with ABT-737 at
75 mg/kg per day i.p. (F) Change in tumor volume in cm3 in six mice per treatment group treated with ABT-737 at 75 mg/kg per day i.p.
and 0.4 mg/kg twice weekly bortezomib i.v. Arrows indicate the days bortezomib was administered.
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cell lines consistently resulted in up-regulation of MCL-1. This was
concurrent with a down-regulation of PAX3-FOXO1 and Noxa (Fig-
ure W1, D and E ). This is consistent with preferential apoptosis in
high PAX3-FOXO1–expressing cells when treated with ABT-737, as
the remaining cells express less Noxa and degrade less MCL-1 pro-
tein. Moreover, overexpression of MCL-1 allows for increased PAX3-
FOXO1 expression (Figure W1F ). ABT-737 has been shown to
synergize with bortezomib in apoptosis induction [38].We also observed
a synergistic effect when we used both drugs in an animal model of
ARMS (Figure 4F), though we also noticed increased toxicity.
We have shown that PAX3-FOXO1 induces Noxa expression in
a p53-independent manner and this is in concurrence with down-
regulation of MCL-1 at the protein level. This up-regulation of Noxa
may contribute to negative selection seen against high PAX3-
FOXO1–expressing cells [35]. Consistent with selection against high
PAX3-FOXO1 expression in primary myoblasts, we have consistently
been unable to overexpress PAX3-FOXO1 to the same level as other
proteins in the same construct, such as PAX3 [10]. Moderate levels of
sustained PAX3-FOXO1 expression induce a small seven-fold increase
in Noxa expression, which alone is not sufficient to induce apoptosis.
However, this level of Noxa expression does reduce prosurvival signals
by decreasing the amount of MCL-1 protein (Figure 2C ). This in-
creases the sensitivity of PAX3-FOXO1–expressing cells to drugs such
as bortezomib and ABT-737, which act to oppose prosurvival signaling.
Some of the ARMS tumor cell lines tested undergo apoptosis in
response to bortezomib treatment. Previous studies using ARMS cell
lines also showed an apoptotic response to bortezomib. Houghton
et al. [22] found that RH30 and RH41 cell lines responded to
bortezomib in vitro. However, when xenografts of the RH30, RH41,
and RH28 tumors (from which the cell lines were derived) were treated
with bortezomib, only RH28 showed inhibition. It should be noted
that Houghton et al. [22] used a bortezomib dose of 1 mg/kg twice
weekly and i.p. administration for which bortezomib has decreased
bioavailability (personal communication from the NCI drug reposi-
tory). We have shown that bortezomib is able to reduce the growth
of RH41 xenografts if administered i.v. at 0.8 mg/kg twice weekly.
RH30 xenografts continued to be nonresponsive to i.v. bortezomib
treatment in vivo. Bersani et al. [21] showed that RH30 was respon-
sive if bortezomib was administered intratumorally at 1.25 mg/kg
twice weekly, which indicates that higher doses are required to induce
Figure 5. In vivo administration of bortezomib inhibits the growth of ARMS tumor xenograft RH41 but not RH30. Six animals were used
per tumor type and treatment group. (A) Change in tumor volume in cm3 as calculated from tumor width and length measurements
following treatment of RH41 xenografts with 0.8 mg/kg twice weekly bortezomib i.v. (B) Survival to morbidity of mice post-RH41 xeno-
graft. (C) Change in tumor volume in cm3 as calculated from tumor width and length measurements following treatment of RH30 xeno-
grafts with 0.8 mg/kg twice weekly bortezomib i.v. (D) Survival to morbidity of mice post-RH30 xenograft.
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apoptosis in RH30 in vivo. Unfortunately intratumoral treatment is
not feasible in humans, particularly those with disseminated disease,
and systemic treatment with such high doses is also not feasible as it
would result in unacceptable toxicity due to the steep dose-response
curve of bortezomib [22]. Therefore, bortezomib may not be the most
appropriate drug with which to target this proapoptotic pathway
in ARMS. Bortezomib functions as a proteasome inhibitor and thus
has numerous other effects on cell biology in addition to Noxa up-
regulation. If a more targeted drug that specifically induced Noxa
expression or mimicked the function of Noxa was developed, we would
predict that this would be a more efficacious molecule than bortezomib,
for the specific induction of apoptosis in PAX3-FOXO1–expressing
cells. Here, we have established that Noxa up-regulation downstream
of PAX3-FOXO1 occurs in ARMS cells and sensitizes these cells to
apoptosis upon treatment with drugs that inhibit prosurvival signals.
How best to exploit this pathway for the treatment of human ARMS
remains to be determined.
Not all ARMS cell lines induced apoptosis in response to bortezomib
treatment. In comparison to our primary myoblast model, where
PAX3-FOXO1 expression results in a reduction of MCL-1 at the
protein level, in ARMS cell lines MCL-1 protein is increased in four
of five lines compared to HSMMs. This does not correlate well with
mRNA expression, indicating that MCL-1 protein stability is enhanced
in some ARMS cell lines. Moreover, two of five ARMS cell lines are
resistant to bortezomib even at 10× the dose required to kill the other
three of five cell lines and mouse primary myoblasts expressing PAX3-
FOXO1. Bortezomib resistance in cancer cells can be conferred by
mutation or up-regulation of proteasome machinery or up-regulation
of drug efflux pumps [39]. However, this is apparently not the case
in ARMS cell lines as bortezomib treatment causes a similar increase
in Noxa expression in both bortezomib-sensitive and bortezomib-
resistant ARMS cell lines. This indicates that bortezomib inhibits the
proteasome in all ARMS cells and causes Noxa up-regulation through
the unfolded protein response [11]. Therefore, we looked downstream
of Noxa in the apoptosis pathway. No association was found between
the expression of members of the mitochondrial apoptotic pathway
and bortezomib resistance (Figure 3C). Moreover, none of the proteins
thought to mediate the Noxa proapoptotic signal were mutated to
prevent apoptosis signaling. All ARMS cell lines are capable of under-
going caspase-dependent apoptosis as ABT-737 produced an apoptotic
response in all five ARMS cell lines.
Though we were unable to determine the mechanism by which
ARMS cell lines RH4 and RH3 become resistant to Noxa induc-
tion by bortezomib, the fact that they are resistant may indicate an
important aspect of ARMS tumor biology. ARMS tumors appear
to posttranslationally increase MCL-1 protein expression compared to
HSMMs and, in some cases, can also become completely resistant to
Noxa induction by bortezomib. This suggests that ARMS tumor cell
lines develop the means to adapt to increased Noxa expression and, in
some cases, completely overcome its proapoptotic effects. We envisage
that a similar path to resistance could develop in ARMS tumors.
In this study, we have identified Noxa as a protein specifically
upregulated downstream of PAX3-FOXO1 expression in primary
myoblasts. This up-regulation of a proapoptotic protein by PAX3-
FOXO1 results in an increased sensitivity of cells to anticancer drugs
such as GSI1, bortezomib, and ABT-737. Therefore, this study
demonstrates that this ARMS-specific Noxa-driven apoptosis pathway
represents a novel target for specific therapy against PAX3-FOXO1–
expressing ARMS tumor cells.
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Figure W1. PAX3-FOXO1 does not regulate MCL-1 on the mRNA level. (A) Relative mRNA expression of mouse MCL-1 determined by
an average of two independent experiments by real-time RT-PCR and normalized to GAPDH expression in primary myoblasts expressing
PAX3-FOXO1 (PF) or empty vector (Empty). (B) Percentage of trypan blue–stained (non-viable cells) Arf−/− primary myoblasts expressing
either a nontargeting (shNT) or Noxa-targeting (shNoxa) shRNA in control (Empty) and PAX3-FOXO1 myoblasts in the presence of 50 nM
bortezomib. (C) Representative relative caspase activity in Arf−/− primary myoblasts expressing either a nontargeting (shNT) or Noxa-
targeting (shNoxa) shRNA in control (Empty) and PAX3-FOXO1 myoblasts in the presence of 1 μM ABT-737. Values are expressed as fold
over appropriate controls. (D) PAX3-FOXO1, MCL-1, and Noxa expression upon treatment of PAX3-FOXO1 (PF) or empty vector (Empty)
expressing ARF−/− primary myoblasts with ABT-737. (E) PAX3-FOXO1 and MCL-1 expression upon treatment of ARMS cell lines with
ABT-737. Noxa expression was below detection. (F) Retroviral empty vector (Empty) and MCL-1 overexpression (MCL1) in empty vector
and PF-expressing myoblasts, in which MCL1 overexpression allows increased PAX3-FOXO1 expression. (G) Immunoprecipitation of
lysates of DMSO- or 50 nM bortezomib–treated Rh30 and RH4 cell myoblasts using control IgG or anti–MCL-1 antibodies followed by
Western blot for MCL-1 or Noxa.
Figure W2. Bortezomib treatment reduces proportional viable tumor area in subcutaneous tumors derived from Arf−/− primary myoblasts
expressing E7 and PAX3-FOXO1. (A) Hematoxylin and eosin (H&E) stained Arf−/− primary myoblasts expressing E7 and PAX3-FOXO1 tumor
cross sections treated with i.v. PBS vehicle or bortezomib. (B) Quantitation of viable area of tumors based on hematoxylin staining of viable
nuclei. (C) Quantitation of area positive for MCL-1 staining in tumor samples. (D) Quantitation of area positive for cleaved caspase 3 staining
in tumor samples. (B, C) The proportion of tumor with positive staining represented in a box plot, significance determined by the Student’s
t test.
Figure W3. Bortezomib treatment reduces proportional viable tumor area in subcutaneous tumors derived from RH41 xenografts. (A) H&E
stained RH41 xenograft tumor cross sections treated with i.v. PBS vehicle or bortezomib. (B) Quantitation of viable area of tumors based on
hematoxylin staining of viable nuclei. (C) Quantitation of area positive for MCL-1 staining in tumor samples. (D) Quantitation of area positive
for cleaved caspase 3 staining in tumor samples. (B, C) The proportion of tumor with positive staining represented in a box plot, significance
determined by the Student’s t test.
Figure W4. Bortezomib treatment reduces proportional viable tumor area in subcutaneous tumors derived from RH30 xenografts. (A) H&E
stained RH30 xenograft tumor cross sections treated with i.v. PBS vehicle or bortezomib. (B) Quantitation of viable area of tumors based on
hematoxylin staining of viable nuclei. (C) Quantitation of area positive for MCL-1 staining in tumor samples. (D) Quantitation of area positive
for cleaved caspase 3 staining in tumor samples. (B, C) The proportion of tumor with positive staining represented in a box plot, significance
determined by the Student’s t test.
